Overview

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.
Phase:
N/A
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Rituximab